PDS Biotechnology Corporation

139 articles with PDS Biotechnology Corporation

• PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019

  11/25/2019

  PDS Biotechnology Corporation announced that Lauren V. Wood, M.D., Chief Medical Officer of PDS Biotechnology, has been selected to deliver an oral presentation on the Company’s novel T-cell activating immunotherapy platform, Versamune®, at the World Vaccine & Immunotherapy Congress West Coast 2019, taking place on December 2-5, 2019 in San Francisco, CA.

• PDS Biotechnology Reports Third Quarter 2019 Financial Results and Provides Business Update

  11/7/2019

  PDS Biotechnology Corporation, a clinical-stage immuno-oncology company developing multiple therapies based on T-cell activating technology called Versamune® announced its financial results for the third quarter ended September 30, 2019.

• PDS Biotechnology Completes Manufacturing of Clinical Batches of PDS0101Clinical batches support upcoming Phase 2 PDS101 combination trials with Merck and National Cancer Institute

  10/22/2019

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering development of multi-functional novel immunotherapies, today announced that it has completed manufacturing of clinical batches of PDS0101 with its partner BSP Pharmaceuticals S.p.A, a leading manufacturer of anticancer drugs.

• PDS Biotechnology Corp. Announces Clinical Collaboration with Merck

  10/3/2019

  PDS0101- KEYTRUDA® (pembrolizumab) Combination to be Evaluated in First Line Treatment of Metastatic Head and Neck Cancer

• PDS Biotechnology Reports Clinical Data for Its Novel Immunotherapy PDS0101 in Follow up to Phase 1 Human Trial

  9/25/2019

  PDS Biotechnology Corporation announced that it has reviewed limited available patient clinical outcome data from its previously reported Phase 1 study.

• PDS Biotechnology Corporation Announces Clinical Collaboration With Merck & Co. To Evaluate Combination Of Versamune PDS0101 And KEYTRUDA (Pembrolizumab) For Metastatic Head And Neck Cancer

  7/10/2017

• BIO2016: PDS Biotechnology Corporation CEO Frank Bedu-Addo Presenting At BIO 2016

  6/7/2016

• PDS Biotechnology Corporation Reports Positive Phase 1 Study Results For PDS0101 Immunotherapy For HPV-Related Cancers

  4/13/2016

• PDS Biotechnology Corporation Signs Agreement With NCI To Form Phase II Clinical Collaboration For Novel Cancer Immunotherapies Based On PDS' Versamune Platform Technology

  2/9/2016

• Immunotherapy Company PDS Biotechnology Corporation Strengthens Senior Management Team, Adds Two Drug Development Executives

  1/20/2016

• PDS Biotechnology Corporation Reports Positive Phase I Clinical Trial Results In Proprietary HPV-Cancer Immunotherapy

  5/28/2015

• PDS Biotechnology Corporation Announces Appointment Of Biotech Industry Leader Sir Richard Sykes To Its Board Of Directors As Executive Chairman

  12/18/2014

• NetScientific Invests In Next Generation, Immunotherapeutics Company, PDS Biotechnology Corporation

  12/15/2014

• PDS Biotechnology Corporation Announces Treatment Of First Patient With PDS0101 Based On The Novel Versamune™ Cancer Immunotherapy Platform In A Phase 1 Clinical Trial

  2/10/2014

• PDS Biotechnology Corporation Signs Worldwide Licensing Agreement With Merck KGaA for Versamune™

  7/9/2012

• PDS Biotechnology Corporation Awarded $1.28M National Cancer Institute Contract

  3/2/2010

• PDS Biotechnology Corporation Demonstrates Pre-Clinical Safety of its Versamune(TM)-Based HPV Product

  10/6/2009

• PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG

  2/24/2009

• PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies

  11/7/2008